These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35151002)

  • 1. Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors.
    Bian S; Shang M; Sawan M
    Biosens Bioelectron; 2022 May; 204():114054. PubMed ID: 35151002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Optical Biosensing of SARS-CoV-2 Spike Proteins in Artificial Samples.
    Tao Y; Bian S; Wang P; Zhang H; Bi W; Zhu P; Sawan M
    Sensors (Basel); 2022 May; 22(10):. PubMed ID: 35632177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients.
    Hao Y; Yang HS; Karbaschi M; Racine-Brzostek SE; Li P; Zuk R; Yang YJ; Klasse PJ; Shi Y; Zhao Z
    Biosens Bioelectron; 2022 Aug; 209():114237. PubMed ID: 35447596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay.
    Mousa ZS; Abdulamir AS
    Arch Razi Inst; 2022 Feb; 77(1):391-402. PubMed ID: 35891753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
    Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
    Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1
    Michos A; Tatsi EB; Filippatos F; Dellis C; Koukou D; Efthymiou V; Kastrinelli E; Mantzou A; Syriopoulou V
    Vaccine; 2021 Sep; 39(40):5963-5967. PubMed ID: 34400017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.
    Filippatos F; Tatsi EB; Papagiannopoulos C; Syriopoulou V; Michos A
    J Virol Methods; 2023 Jun; 316():114728. PubMed ID: 37028561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.
    Resman Rus K; Korva M; Knap N; Avšič Županc T; Poljak M
    J Clin Virol; 2021 Jun; 139():104820. PubMed ID: 33865031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody.
    Duan X; Shi Y; Zhang X; Ge X; Fan R; Guo J; Li Y; Li G; Ding Y; Osman RA; Jiang W; Sun J; Luan X; Zhang G
    Biosens Bioelectron; 2022 Mar; 199():113883. PubMed ID: 34942543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.
    Demers-Mathieu V; Hakansson AP; Hall S; Lavangnananda S; Fels S; Medo E
    Breastfeed Med; 2022 Feb; 17(2):163-172. PubMed ID: 34809492
    [No Abstract]   [Full Text] [Related]  

  • 17. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
    Niu L; Wittrock KN; Clabaugh GC; Srivastava V; Cho MW
    Front Immunol; 2021; 12():647934. PubMed ID: 33995366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.